NCT07096882View on ClinicalTrials.gov

SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection

PHASE1RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 26, 2025

Primary Completion Date

June 26, 2027

Study Completion Date

June 26, 2029

Conditions
Non-Small Cell Lung Cancer
Interventions
BIOLOGICAL

SDT-M001 injection

Cascade primed immune cells(CAPRI); SDT-M001 injection is administered at three dose levels:1.5e9 cells, 3e9 cells,6e9 cells. The cells will be reinfused in 3 divided doses, administered every other day, and the total process will take 5 days.

Trial Locations (1)

610000

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Cytocraft Biopharmaceutical Co., Ltd.

INDUSTRY